(Q36719691)

15 August 2017

1 reference

title

Memantine in the treatment of mild-to-moderate Alzheimer's disease (English)

1 reference

15 August 2017

0 references

Kelly M Cosman

1

1 reference

15 August 2017

Lisa L Boyle

series ordinal

2

1 reference

15 August 2017

Anton P Porsteinsson

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

2

1 reference

15 August 2017

203-214

1 reference

Alzheimer Disease in the US Population

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Dementia and Alzheimer disease incidence: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Identification of Alzheimer disease risk by functional magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Neuroimaging as a marker of the onset and progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Glutamate transmission and toxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Delayed neurotoxicity of excitatory amino acids in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Depression in Alzheimer's disease: overview and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Beta-secretase (BACE) as a drug target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

gamma-secretase as a therapeutic target for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Statins: drugs for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Alzheimer's associated inflammation, potential drug targets and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Current Treatment for Alzheimer Disease and Future Prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

Pharmacokinetic study of memantine in healthy and renally impaired subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.203

21 January 2018

Identifiers

DOI

10.1517/14656566.8.2.203

1 reference

15 August 2017

1 reference